Steven Powell, an experienced biotech executive, has been named chief executive of the France-based start-up company Ribonexus SAS. Ribonexus is building a pipeline of potential oncology drugs that target eurkaryotic initiation factor-4A, a protein thought to be associated with a patient’s resistance to current therapies. Dr Powell has a PhD in microbiology from the University of Aberdeen in the UK. He was most recently CEO of Etherna Immunotherapies NV in Belgium.
Ribonexus announced the appointment on 14 December 2022.
Copyright 2022 Evernow Publishing Ltd